SAN FRANCISCO , Dec. 04, 2024 (GLOBE NEWSWIRE) -- Investors in Edwards Lifesciences Corporation (NYSE: EW) contend that the medical device giant misled them about the growth prospects of its core product, the Transcatheter Aortic Valve Replacement (TAVR) platform. A class action lawsuit has been filed, accusing the company of securities fraud and claiming that executives painted a misleading picture of TAVR's future growth potential. Hagens Berman urges Edwards Lifesciences Corporation investors who suffere ...

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Edwards Lifesciences Corporation ("Edwards Lifesciences " or the "Company") (NYSE: EW) investors of a class action representing investors that bought securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"). Edwards Lifesciences investors have until December 13, 2024 to file a lead plaintiff motion. Investors are en ...

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Dec. 2, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, all dates inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit.  Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit ch ...

NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

RADNOR, Pa., Nov. 28, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Edward ...

NEW YORK, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a class action (Case No. 24-cv-02221) was filed on behalf of all investors who purchased or otherwise acquired Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024. Edwards is an international company that researches, develops, and provides products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions.For more information, submit ...

Edwards Lifesciences (EW) has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s SAPIEN valve platform, backed by multiple years of follow-up and more than 10 years of clinical experience with the RESILIA tissue.The latest development should bolster Edwards’ Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart groups. The findings were simultaneously published in the J ...